GlaxoSmithKline starts using Apple's ResearchKit for a rheumatoid arthritis study, becoming the first drugmaker to use the framework for clinical research
Glaxo is the first drugmaker to use Apple's ResearchKit — Success of the trial will determine Glaxo's future adoption
Context & Ripple Effects
Apple launched ResearchKit in March 2015 as an open framework for medical researchers to collect data through iPhone apps, and by that summer GlaxoSmithKline and Purdue Pharma were openly weighing it for drug R&D. A year later, Glaxo has converted that consideration into commitment: it is running a rheumatoid arthritis clinical study on the framework, making it the first drugmaker to do so.
The significance is regulatory and reputational rather than technical. Academic apps like MyHeart Counts — which expanded beyond the US to the UK and Hong Kong — proved the framework could recruit patients at scale, but a pharmaceutical sponsor running it inside an actual clinical program tests whether iPhone-collected data can survive the scrutiny a drug trial demands.
First-order effects
- Glaxo's rheumatoid arthritis study now recruits and monitors participants through ResearchKit apps instead of conventional site-only methods, directly testing whether the framework can lower enrollment friction in a regulated trial.
- Apple gets its first pharmaceutical-company endorsement of ResearchKit, upgrading the framework from academic research tool to something with a validated path into drug development.
Second-order effects
- Purdue Pharma, named alongside Glaxo in last year's coverage as a potential adopter, now has a working precedent to evaluate — and if the trial succeeds, other drugmakers face a demonstrated cheaper recruitment channel their competitors are already using.
- The result puts pressure on contract research organizations and traditional trial-site operators, whose enrollment economics are what ResearchKit's low-friction model undercuts.
Third-order effects
- If Glaxo's trial validates the approach, smartphone-based data collection moves from adjunct to core infrastructure in clinical research, shifting the gatekeeping of patient data toward platform owners like Apple and forcing regulators to formalize standards for app-sourced endpoints.
- Pharma R&D budgets would begin reallocating toward digital recruitment and remote monitoring, changing which intermediaries capture value in the trial supply chain.
The trend: Consumer hardware platforms are moving from wellness apps into regulated clinical research, with each successful pharma trial converting skepticism about app-sourced medical data into adoption.